Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000198278 | SCV000254510 | likely benign | Neurofibromatosis, type 1 | 2025-01-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002315628 | SCV000663062 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-03-12 | criteria provided, single submitter | clinical testing | The p.H2436R variant (also known as c.7307A>G), located in coding exon 49 of the NF1 gene, results from an A to G substitution at nucleotide position 7307. The histidine at codon 2436 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV000681024 | SCV000808475 | uncertain significance | not provided | 2020-09-03 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000198278 | SCV002561064 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003462327 | SCV004198242 | uncertain significance | Juvenile myelomonocytic leukemia | 2023-10-22 | criteria provided, single submitter | clinical testing |